Company Encyclopedia
View More
name
ER-KANG
300267.SZ
Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally. The company offers various APIs, such as glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. It also provides finished drugs, including sulbenicillin sodium for injection and compound liquorice tablets. In addition, the company offers conventional pharmaceutical excipients include pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprise hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate products.
3.095 T
300267.SZMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking123/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-6.71%D
    • Profit Margin-23.87%E
    • Gross Margin27.61%C
  • Growth ScoreC
    • Revenue YoY8.36%B
    • Net Profit YoY-18.20%D
    • Total Assets YoY-3.55%D
    • Net Assets YoY-6.09%D
  • Cash ScoreC
    • Cash Flow Margin-418.95%E
    • OCF YoY8.36%B
  • Operating ScoreD
    • Turnover0.24D
  • Debt ScoreA
    • Gearing Ratio15.20%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ER-KANG: The net profit for the third quarter was 1.9412 million yuan, a year-on-year increase of 106.11%

    ER-KANG announced that its revenue for the third quarter was 325 million yuan, a year-on-year increase of 39.32%; net profit was 1.9412 million yuan, a year-on-year increase of 106.11%. Revenue for the first three quarters was 1.006 billion yuan, a year-on-year increase of 17.81%; net profit was 39.5759 million yuan, a year-on-year increase of 255.40%

    Zhitong·
    SZ
    300267
    +1.14%
    Zhitong·
    SZ
    300267
    +1.14%

    ER-KANG: The controlling shareholder plans to reduce its holdings by no more than 2.04%

    According to the Zhitong Finance APP, ER-KANG announced that the company's controlling shareholder, Shuai Fangwen, plans to reduce his holdings of the company's shares by no more than 42 million shares, or no more than 2.04% of the company's total share capital, through centralized bidding or block trading within three months after the announcement date (from October 29, 2025, to January 28, 2026)

    Zhitong·
    SZ
    300267
    +1.14%
    Zhitong·
    SZ
    300267
    +1.14%

    Hunan Er-Kang Pharmaceutical's controlling shareholder plans to unload stake

    Sept 29 (Reuters) - Hunan Er-Kang Pharmaceutical Co Ltd:says controlling shareholder plans to unload up to 2% stake in co between October 29 and January 28, 2026(Reporting by Beijing Newsroom)

    marketscreener·
    SZ
    300267
    +1.14%
    marketscreener·
    SZ
    300267
    +1.14%

    ER-KANG released its performance for the first half of the year, with a net profit attributable to the parent company of 37.6346 million yuan, an increase of 497.36%

    ER-KANG released its semi-annual report for 2025, with operating revenue of 682 million yuan, a year-on-year increase of 9.74%. The net profit attributable to shareholders of the listed company was 37.6346 million yuan, a year-on-year increase of 497.36%. The net profit after deducting non-recurring gains and losses was 33.0187 million yuan, a year-on-year increase of 1357.97%. The basic earnings per share were 0.0182 yuan

    Zhitong·
    SZ
    300267
    +1.14%
    Zhitong·
    SZ
    300267
    +1.14%

    ER-KANG: Dihydroxypropyl Theophylline Injection approved for registration

    ER-KANG recently obtained the "Drug Registration Certificate" issued by the National Medical Products Administration, and its dihydroxypropyl theophylline injection has been approved for registration. This medication is a smooth muscle relaxant that has the effect of dilating the bronchi and coronary arteries, suitable for conditions such as bronchial asthma and wheezing bronchitis, especially for patients with tachycardia

    Zhitong·
    SZ
    300267
    +1.14%
    Zhitong·
    SZ
    300267
    +1.14%
    © 2025 Longbridge｜Disclaimer